AMENDMENTS TO THE CLAIMS

1. **Cancelled**

2. **Cancelled**

3. **Cancelled**

4. **(Currently Amended)** An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 14;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide;

(c) ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234;

(d) ~~the amino acid sequence of the extracellular domain~~ a polypeptide comprising amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14, ~~including its associated signal peptide~~ wherein said other portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 is selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579;

~~wherein said extracellular domain is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14; and~~

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin tissue or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin tissue.

5. **(Currently Amended)** The isolated polypeptide of Claim 4 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 14;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide;

(c) ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234;

(d) ~~the amino acid sequence of the extracellular domain~~ a polypeptide comprising amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14, ~~including its associated signal peptide~~ wherein said other portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 is selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579;

~~wherein said extracellular domain is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14; and~~

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin tissue or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin tissue.

6. **(Currently Amended)** An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 14;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide;

(c) ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234;

(d) ~~the amino acid sequence of the extracellular domain~~ a polypeptide comprising amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of

the amino acid sequence of the polypeptide of SEQ ID NO: 14, ~~including its associated signal peptide~~ wherein said other portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 is selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579~~;~~.

~~wherein said extracellular domain is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14.~~

7. **(Previously Presented)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 14.

8. **(Previously Presented)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide.

9. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14~~, wherein said extracellular domain is~~ selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14.

10. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising ~~the amino acid sequence of the extracellular domain~~ amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14~~, including its associated signal peptide, wherein said extracellular domain~~ wherein said other portion is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14.

11. **(Original)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579.

12. **(Previously Presented)** A chimeric polypeptide comprising a polypeptide according to Claim 4 fused to a heterologous polypeptide.

13. **(Previously Presented)** The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

14. **(Currently Amended)** An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 14;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide;

(c) ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234;

(d) ~~the amino acid sequence of the extracellular domain~~ a polypeptide comprising amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14, ~~including its associated signal peptide~~ wherein said other portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 is selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579;

~~wherein said extracellular domain is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14; and~~

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 14 in skin tissue samples.

15. **(Currently Amended)** The isolated polypeptide of Claim 14 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 14;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 14, lacking its associated signal peptide;

(c) ~~the amino acid sequence of the extracellular domain~~ a portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234;

(d) ~~the amino acid sequence of the extracellular domain~~ a polypeptide comprising amino acids 1-20 of the polypeptide of SEQ ID NO: 14 and another portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14, ~~including its associated signal peptide~~ wherein said other portion of the amino acid sequence of the polypeptide of SEQ ID NO: 14 is selected from the group consisting of amino acids 21-53, amino acids 119-129, and amino acids 167-234; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203579;

~~wherein said extracellular domain is selected from the group consisting of amino acids 21-53 of SEQ ID NO: 14, amino acids 119-129 of SEQ ID NO: 14, and amino acids 167-234 of SEQ ID NO: 14; and~~

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 14 in skin tissue samples.

16. **(Previously Presented)** A chimeric polypeptide comprising a polypeptide according to Claim 14 fused to a heterologous polypeptide.

17. **(Previously Presented)** The chimeric polypeptide of Claim 16, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.